Image de couverture de livre

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Brent A. Neuschwander‐Tetri, Heather L. Morris, Andrea R. Mospan, Feng Yu, Breda Munoz, Sheenu Abraham, Michael W. Fried, A. Sidney Barritt, Leen Al‐Sayyed, Arun J. Sanyal
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
par: Mary Yue Wang, et autres
Publié: (2025)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
par: Raj Vuppalanchi, et autres
Publié: (2024)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
par: Maral Amangurbanova, et autres
Publié: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
par: Xiaojuan Liu, et autres
Publié: (2025)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
par: Mohamed El‐Kassas, et autres
Publié: (2025)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
par: Mazen Noureddin, et autres
Publié: (2025)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
par: Mark C. C. Cheah, et autres
Publié: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
par: Margaret L. P. Teng, et autres
Publié: (2024)

Editorial: Cholestasis Is an Important Marker for Evaluating Clinical Outcomes and Prognosis in Severe Burns and Critically Ill Patients
par: Andrew T. Roberts, et autres
Publié: (2026)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
par: Aisha Alawi, et autres
Publié: (2025)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
par: Maryam Zafer, et autres
Publié: (2024)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
par: Ganesh Bhat, et autres
Publié: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
par: Jiru Li, et autres
Publié: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
par: Hannah Mohr, et autres
Publié: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
par: Suzanne Sharpton, et autres
Publié: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
par: Amol N. Patil, et autres
Publié: (2026)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
par: Vincent L. Chen
Publié: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
par: R. Sinha, et autres
Publié: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
par: Hassan Javed, et autres
Publié: (2025)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
par: Wah‐Kheong Chan, et autres
Publié: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
par: Nobuharu Tamaki, et autres
Publié: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
par: Federico Perna, et autres
Publié: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
par: Takefumi Kimura
Publié: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
par: Mohamed El‐Kassas, et autres
Publié: (2025)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
par: Niharika Samala, et autres
Publié: (2024)

The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease
par: Sebastiaan ten Bokkel Huinink, et autres
Publié: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
par: Eduardo Vilar‐Gomez, et autres
Publié: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
par: Qiang Hu, et autres
Publié: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
par: Darren Jun Hao Tan, et autres
Publié: (2024)

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
par: Carlos José Pirola, et autres
Publié: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
par: Stuart McPherson, et autres
Publié: (2024)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
par: Sofia Tsitsou, et autres
Publié: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
par: Yewan Park, et autres
Publié: (2024)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
par: Supachaya Sriphoosanaphan, et autres
Publié: (2025)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
par: Daniela S. Allende, et autres
Publié: (2024)

Editorial on ‘Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’
par: Ming Chao Tsai, et autres
Publié: (2025)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
par: Philippe Sultanik, et autres
Publié: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
par: Wenjun Meng, et autres
Publié: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
par: Junbin Yan, et autres
Publié: (2024)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
par: Donghee Kim, et autres
Publié: (2025)